Search form
Search
contact us
Navigation
home
boards
Jobs
job ratings
cp wire
medtech news
pharmagather
catering
advertise
whistleblower info
pharmaceutical fraud
medical device | DME fraud
clinical lab fraud
False Claims Act
Legal Help
login/register
You are here
Home
»
companies
» Imbruvica
Imbruvica
Top 40 Best-Selling Oncology Drugs in 2023 by 2022 Data
Xtalks
Mon, 02/5/24 - 10:17 am
oncology
cancer
Keytruda
Revlimid
Opdivo
Imbruvica
Darzalex
Merck
Bristol Myers Squibb
AbbVie
Janssen
Despite big Q2 declines for Humira and Imbruvica, AbbVie still boosts earnings guidance
Fierce Pharma
Thu, 07/27/23 - 11:37 pm
AbbVie
earnings
Humira
biosimilars
Imbruvica
AbbVie sues BeiGene over brand-new Imbruvica patent as blood cancer rivalry heats up
Fierce Pharma
Fri, 06/16/23 - 09:44 am
AbbVie
Pharmacyclics
BeiGene
Brukinsa
patents
Imbruvica
blood cancer
AbbVie removes two approvals for blood cancer drug Imbruvica
BioPharma Dive
Fri, 04/7/23 - 01:49 pm
AbbVie
Imbruvica
cancer
BeiGene's Brukinsa wins CLL approval after topping Imbruvica in head-to-head trial
Endpoints
Thu, 01/19/23 - 08:55 pm
BeiGene
Brukinsa
CLL
FDA
Imbruvica
BeiGene heaps more pressure on AbbVie, J&J with new Brukinsa head-to-head win over Imbruvica
Fierce Pharma
Wed, 10/12/22 - 11:00 am
BeiGene
AbbVie
JNJ
Imbruvica
blood cancers
Brukinsa
AbbVie, J&J's Imbruvica wins first pediatric nod, this one for chronic graft-versus-host disease
Fierce Pharma
Thu, 08/25/22 - 11:04 am
JNJ
AbbVie
Imbruvica
graft vs host disease
pediatric
FDA
Janssen's Imbruvica Demonstrates Significant Survival Outcomes In Older Lymphoma Patients
BioSpace
Mon, 06/6/22 - 10:03 am
ASCO 2022
JNJ
Janssen
Imbruvica
clinical trials
lymphoma
ASCO: J&J, AbbVie go back to Imbruvica's roots in lymphoma. Will lack of survival win matter?
Fierce Pharma
Fri, 06/3/22 - 10:27 am
AbbVie
JNJ
ASCO 2022
FDA
Imbruvica
MCL
AbbVie files sNDA to FDA for chronic graft versus host disease therapy
Pharmaceutical Business Review
Tue, 03/1/22 - 10:24 am
AbbVie
Imbruvica
graft vs host disease
FDA
ASH: Chasing AbbVie and J&J's Imbruvica, BeiGene's Brukinsa fleshes out competitive leukemia data again
Fierce Biotech
Thu, 11/4/21 - 10:27 am
BeiGene
Brukinsa
leukemia
clinical trials
AbbVie
JNJ
Imbruvica
Court upholds AbbVie's patents on blockbuster cancer drug Imbruvica, generics unlikely until 2032
Endpoints
Fri, 08/20/21 - 12:33 pm
AbbVie
Imbruvica
patents
legal
generics
In next-gen BTK battle, AbbVie and J&J tout pivotal data backing Imbruvica as a combo treatment
Endpoints
Mon, 06/14/21 - 10:29 am
AstraZeneca
JNJ
AbbVie
clinical trials
CLL
Gazyva
Imbruvica
Venclexta
This Is Why Humira Isn't AbbVie's Biggest Problem Right Now
Motley Fool
Mon, 05/3/21 - 10:55 am
AbbVie
Humira
patents
patent cliff
Imbruvica
AZ says Calquence is a safer drug than Imbruvica
Pharmaforum
Mon, 01/25/21 - 11:02 am
AstraZeneca
Calquence
Imbruvica
JNJ
AbbVie
CLL
ASH: AstraZeneca's Calquence, BeiGene's Brukinsa turn heads with new data, putting Imbruvica on notice
Fierce Pharma
Sun, 12/6/20 - 07:15 pm
AstraZeneca
BeiGene
JNJ
AbbVie
Calquence
Brukinsa
Imbruvica
CLL
ASH2020
Janssen gets expanded EC nod for blood cancer combo drug Imbruvica plus rituximab
Pharmaceutical Business Review
Tue, 09/8/20 - 10:41 am
JNJ
Janssen
Europe
Imbruvica
rituximab
CLL
AbbVie to face House committee subpoena over Humira, Imbruvica pricing strategies: chairwoman
Fierce Pharma
Tue, 09/1/20 - 12:28 pm
AbbVie
Imbruvica
Humira
drug pricing
patents
AbbVie, already famous for its Humira strategy, forms another 'patent wall' around Imbruvica: report
Fierce Pharma
Wed, 07/22/20 - 11:47 pm
AbbVie
Humira
patents
Imbruvica
cancer
AbbVie, J&J blockbuster Imbruvica rakes in 11th FDA approval, as competitors work on eroding franchise
Endpoints
Wed, 04/22/20 - 10:43 am
AbbVie
JNJ
Imbruvica
FDA
CLL
SLL
Pages
1
2
3
4
5
6
7
next ›
last »